Spatial-hindrance-based pro-Adalimumab prevents anti- idiotypic antibody interference in pharmacokinetic and therapeutic efficacy2025-11-14DownloadsRead MoreSpatial-hindrance-based pro-Adalimumab prevents anti- idiotypic antibody interference in pharmacokinetic and therapeutic efficacy
Specific-activation-of-pro-Infliximab-enhances-selectivity-and-safety-of-rheumatoid-arthritis-therapy2021-10-14DownloadsRead MoreSpecific-activation-of-pro-Infliximab-enhances-selectivity-and-safety-of-rheumatoid-arthritis-therapy
Get In Touch We can't wait to hear from you！ Contact Us +886 7 311 1577 ｜Taipei office｜ 17F, No. 3, Park St., Nangang Dist., Taipei City 115, Taiwan Kaohsiung office｜ 12F, 1st Teaching Building, 100, Shih-Chuan 1st Rd., Sanmin Dist., Kaohsiung 807, Taiwan Home About Technical Capabilities Pipeline Antibody LockTM Platform News Partner & Investor Contact Stay Connected If you see this, Happy New Year! If you see this, Happy New Year!
